eXoZymes prices $5.33M offering of common stock and warrants at $18/unit

EXOZYMES INC.

Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.
Warrants exercisable after 1 year at $11.24/share, expire in 5 years; redeemable at $0.01 if stock ≥ $17.98.
Underwriter MDB Capital; over-allotment option for additional 44,420 units (45 days).
Net proceeds to fund NCT development, R&D, and general corporate purposes; close expected June 9, 2026.
Warrant exercise price resets to $0.001 if Company sells shares below $8.99 within 12 months (subject to holding requirement).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

EXOZYMES INC. entered into Underwriting Agreement with MDB Capital valued at approximately $5,330,430 (effective 2026-06-05).

Action: entry
Agreement: underwriting
Counterparty: MDB Capital
Value: approximately $5,330,430
Effective: 2026-06-05

Exact text from the filing

On June 5, 2026, eXoZymes Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of June 5, 2026, with MDB Capital (“MDB”), as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering (the “Offering”) an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Common Stock”), of the Company and 292,135 warrants to purchase up to an aggregate of 292,135 shares of Common Stock (the “Warrants”).

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

EXOZYMES INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-027688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.